Pharmaceutical Technology on MSN3d
BMS to acquire longtime cell therapy partner 2seventy bio for $286mThe deal comes after a challenging few years for 2seventy bio, which had divested research programmes in recent years.
2seventy bio worked with BMS on the development of BCMA-directed CAR-T therapy Abecma (idecabtagene vicleucel), used to treat ...
The deal caps a turbulent three years for 2seventy bio. The company served as the oncology business of Bluebird Bio until Bluebird spun out 2seventy in 2021.
More than a year into a strategic pivot to zero in on the multiple myeloma cell therapy Abecma, 2seventy bio is selling ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback